If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -50.6% over the past 5 years. This target conveys her confidence in NTLA’s ability to climb 50% higher in the next year. With the average price target clocking in at $51.67, shares could jump 61% in the next year. Price Vs S&P500. The company’s shares have gained +44.84% over the past 6 months, with this year growth rate of 10.9%, compared to 12.7% for the industry. 4 Buys, 1 Hold and 1 Sell have been issued in the last three months, so the word on the Street is that VIR is a Moderate Buy. Intellia Therapeutics, Inc. Common Stock (NTLA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Medium Cap Stock Quidel Corporation (QDEL) is a Overweight – Analysts. None have rated the stock as Underweight. Intellia explicitly disclaims any obligation to update any forward-looking statements, except as required by law. Is it time for the bears to break out the champagne glasses? 6218, or by email at syndicate@svbleerink.com; or by accessing the SEC’s website at www.sec.gov. After its fiscal Q4 earnings results blew estimates out of the water, Goldman Sachs believes this stock has more room to run.In the most recent quarter, PTON posted revenue of $607.1 million, beating the $586.2 million consensus estimate and reflecting a 172% year-over-year increase. Despite being -1.55% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Aug 31 when the NTLA stock price touched $22.76- or saw a rise of 20.39%. All of the shares in the offering are to be sold by Intellia. Investors could be pocketing a gain of 53%, should this target be met in the twelve months ahead. Short interest in the company has seen 10.96 Million shares shorted with days to cover at 0.01. Is Kinder Morgan, Inc. (NYSE:KMI) Expensive At $12.73? Proof-of-concept data for lead program NTLA-2001, its therapy targeting transthyretin amyloidosis (ATTR), a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues, could come by mid-2021. The company, which offers exercise bikes and remote workout classes, rose to fame at the start of the COVID-19 pandemic. (To watch Choi’s track record, click here)Is the rest of the Street in agreement? Initial data is set to be released by the end of 2020, with top-line data expected in January. Interactive Chart. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the public offering filed with the SEC. 8 analysts offering their estimates for the company have set an average revenue estimate of $15.38 Million for the current quarter. On top of this, the strategist argues the vaccine’s arrival will push U.S. GDP growth to 6%, compared to the 3.9% consensus estimate.Given Kostin’s outlook, we wanted to check out three stocks scoring major praise from Goldman Sachs. “While we note the limited economics to NTLA from this program and competitor dynamics with bluebird bio’s (BLUE) LentiGlobin and CRISPR Therapeutics’ (CRSP) CTX001 that are ahead in clinical development, the study should serve as proof-of-concept for the platform. That being said, Terry’s bullish thesis remains very much intact.Expounding on this, the analyst said, “... we believe that the window of opportunity for any meaningful competitor is rapidly closing, something that, along with the large and expanding addressable market for Peloton’s high ARPU, high margin, extremely low churn subscription business, remains underappreciated by the market, even with the stock’s recent outperformance.”It should come as no surprise, then, that Terry stayed with the bulls. Tencent Music Entertainment Group (NYSE:TME) Climbs 112.3% In 2020; Is It Attractive Enough At $14.35? The offering is expected to close on or about June 5, 2020, subject to customary closing conditions. PTON’s Strong Buy consensus rating breaks down into 20 Buys, 2 Holds and 1 Sell. 8 have an estimated revenue figure of $14.81 Million for the next quarter concluding in December 01, 2020. Marketing Sentinel is a free online newspaper packed with exclusive content, news, articles and much more! With it standing at the front of the pack in the COVID-19 monoclonal antibody (mAb) race, it’s no wonder Goldman Sachs likes what it’s seeing.Firm analyst Paul Choi cites a recent data readout from one of VIR’s competitors as reaffirming his confidence. Intellia Therapeutics, Inc. (NASDAQ:NTLA) has a beta value of 1.71 and has seen 1,124,546 shares traded in the last trading session. This data stands to “inform the drug’s clinical profile (safety/tolerability and early signs of sustained TTR knockdown),” which would de-risk NTLA’s in vivo editing platform, in Richter’s opinion.On top of this, IND-enabling studies for NTLA-2002, its therapy designed for hereditary angioedema (HAE), and NTLA-5001, its therapy for WT1+ acute myeloid leukemia (AML), are set to kick off in 2021. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $100 million, excluding any exercise of the underwriters' option to purchase additional shares. The consensus among analysts is that Intellia Therapeutics, Inc. (NTLA) is an Overweight stock at the moment, with a recommendation rating of 2.1. Why Buy stock in Intellia Therapeutics, Inc. (NTLA)? Intellia Therapeutics Announces Pricing of Public Offering of Common Stock. © 2020 Verizon Media. We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, … The majority of other analysts are. “While the company guided fiscal Q1 2021 and FY21 revenue and adjusted EBITDA well above consensus, given the backlog of demand exiting the June quarter and the 6-8 weeks of deliveries already on order by consumers, we expect this guidance will again prove overly conservative,” he explained.This performance prompted Terry to state, “We continue to believe that Peloton represents a significant long-term opportunity as the company is in the earliest stages of creating new and expanding existing categories of connected fitness products, an opportunity that we believe has been permanently accelerated by the current COVID-19 crisis.”It should be noted that the company faces significant risks going forward. NTLA S&P 500 Index News & Analysis: Intellia Therapeutics. None of the analysts rate the stock as a Sell, while 2 rate it as Overweight. The price target for Intellia Therapeutics is set to $33.00. Any forward-looking statements contained in this press release represent Intellia’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The projected low price target is $16 while the price target rests at a high of $37. While we note the initial focus is on delivery to the liver, extrahepatic tissue targeting (i.e. The firm’s total holdings are worth over $130.22 Million and represent 10.55% of shares outstanding. Year-to-date, Intellia Therapeutics, Inc. shares have moved 23.52%, while the 5-day performance has seen it change -15.09%. IA "Marketing Sentinel" seeks to provide the news and analytical information to both American and foreign audiences, events and events in the USA and all over the world reliably, objectively and promptly. Using TipRanks’ database, we found out that all three tickers have gotten a thumbs up from analysts at other firms as well. An in-depth look at the SITE Centers Corp. (SITC) stock. Let's take a closer look.Intellia Therapeutics (NTLA)Focused on utilizing gene editing to develop cell therapies, Intellia Therapeutics wants to stomp out cancer and other immunological diseases for good. CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the pricing of an underwritten public offering of 5,479,453 shares of its common stock at a public offering price of $18.25 per share. For the second quarter, Intellia Therapeutics had an EPS of $0.61, compared to year-ago quarter EPS of $0.56. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Is Mylan N.V. (NASDAQ:MYL) Expensive At $15.27? First data could be presented in 2021,” the analyst commented.All of this prompted Richer to initiate coverage with a Buy rating and $33 price target. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Intellia’s anticipated public offering. Intellia Therapeutics, Inc. (NASDAQ:NTLA) has a beta value of 1.7 and has seen 1,089,063 shares traded in the last trading session. Kyle Dennis took a leap of faith and decided to invest his savings of $15K in the stock market — $2.8M later, he owes his success to these strategies. As of April 29, 2020, the former fund manager holds about 12.02% shares in the company for having 7058132 shares of worth $95.07 Million while later fund manager owns 2.57 Million shares of worth $34.63 Million as of April 29, 2020, which makes it owner of about 4.38% of company’s outstanding stock. This is up from growth of 65.6% in the previous quarter. VIR argues its approach is differentiated given the high barrier to resistance, potent effector function, potential for increased lung tissue concentration and extended half-life.Even though VIR is behind its peers in terms of development timelines, Choi thinks that the company is making substantial progress. The company, currently valued at $1.06 Billion, closed the last trade at $18.12 per share which meant it lost -$0.29 on the day or -1.55% during that session. Wall Street analysts have a consensus price target for the stock at $24.75, which means that the shares’ value could jump 36.59% from current levels. Is Nutanix, Inc. (NASDAQ:NTNX), -65.54% away from high, Poised For A Strong Comeback? Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. (To watch Terry’s track record, click here)In general, other analysts are on the same page. The NTLA stock price is -41.06% off its 52-week high price of $25.56 and 49.34% above the 52-week low of $9.18. It is very important to do your own analysis before making any investment.